Analysts’ Recent Ratings Changes for Intra-Cellular Therapies (ITCI)

by · The Cerbat Gem

Several analysts have recently updated their ratings and price targets for Intra-Cellular Therapies (NASDAQ: ITCI):

  • 2/16/2025 – Intra-Cellular Therapies is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
  • 2/8/2025 – Intra-Cellular Therapies is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
  • 1/31/2025 – Intra-Cellular Therapies was downgraded by analysts at Canaccord Genuity Group Inc. from a “buy” rating to a “hold” rating. They now have a $132.00 price target on the stock, up previously from $119.00.
  • 1/31/2025 – Intra-Cellular Therapies is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
  • 1/23/2025 – Intra-Cellular Therapies is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
  • 1/22/2025 – Intra-Cellular Therapies had its “sector perform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $132.00 price target on the stock, up previously from $108.00.
  • 1/14/2025 – Intra-Cellular Therapies was upgraded by analysts at Cantor Fitzgerald from a “hold” rating to a “strong-buy” rating.
  • 1/14/2025 – Intra-Cellular Therapies had its “neutral” rating reaffirmed by analysts at Piper Sandler. They now have a $132.00 price target on the stock, up previously from $107.00.
  • 1/13/2025 – Intra-Cellular Therapies was downgraded by analysts at Leerink Partnrs from a “strong-buy” rating to a “hold” rating.
  • 1/13/2025 – Intra-Cellular Therapies was downgraded by analysts at Baird R W from a “strong-buy” rating to a “hold” rating.
  • 1/13/2025 – Intra-Cellular Therapies had its “hold” rating reaffirmed by analysts at Needham & Company LLC. They now have a $100.00 price target on the stock.

Intra-Cellular Therapies Trading Up 0.1 %

ITCI stock traded up $0.07 during midday trading on Friday, hitting $128.61. The company’s stock had a trading volume of 562,293 shares, compared to its average volume of 4,171,555. The company has a market cap of $13.67 billion, a PE ratio of -147.82 and a beta of 0.72. Intra-Cellular Therapies, Inc. has a 12 month low of $62.78 and a 12 month high of $128.77. The firm’s 50-day moving average is $109.36 and its 200-day moving average is $89.29.

Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) last released its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. Analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Insider Activity

In other news, CEO Sharon Mates sold 51,000 shares of the company’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total value of $4,375,800.00. Following the completion of the sale, the chief executive officer now directly owns 1,070,329 shares in the company, valued at $91,834,228.20. This represents a 4.55 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders own 2.60% of the company’s stock.

Institutional Investors Weigh In On Intra-Cellular Therapies

Institutional investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. increased its stake in Intra-Cellular Therapies by 10.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company’s stock worth $1,878,000 after buying an additional 2,157 shares in the last quarter. Barclays PLC increased its stake in Intra-Cellular Therapies by 282.0% in the 3rd quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company’s stock worth $2,521,000 after buying an additional 25,435 shares in the last quarter. Oak Ridge Investments LLC increased its stake in Intra-Cellular Therapies by 74.1% in the 4th quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company’s stock worth $1,656,000 after buying an additional 8,440 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in Intra-Cellular Therapies by 31.9% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 454,538 shares of the biopharmaceutical company’s stock worth $33,258,000 after buying an additional 109,892 shares in the last quarter. Finally, Cynosure Group LLC grew its position in shares of Intra-Cellular Therapies by 161.0% during the third quarter. Cynosure Group LLC now owns 14,442 shares of the biopharmaceutical company’s stock valued at $1,057,000 after purchasing an additional 8,909 shares in the last quarter. Hedge funds and other institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.

Read More